This was the stock's second consecutive day of gains.

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

Shares of Gilead Sciences Inc. GILD slid 2.15% to $112.29 Thursday, on what proved to be an all-around rough trading session ...

With Black women and straight men increasingly at risk, Gilead’s Yeztugo may finally offer a discreet, stigma-free way to ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top cheap pharmaceutical stocks to buy now. Morgan Stanley analyst Terence ...

Trump signed a sweeping executive order in May demanding drugmakers cut U.S. medicine prices to match those abroad, saying ...

Among its other ratings, Gilead's Accumulation/Distribution Rating of B shows moderate buying by institutional investors over ...

The largest group of Black physicians, thought leaders, and celebrities were in one room to have a needed discussion about HIV.

Get a deeper insight into the potential performance of Gilead (GILD) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of ...

Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their ...

On July 16, 49 attorneys general (AGs) announced that they joined a $202 million settlement with Gilead Sciences, Inc. (Gilead). Previously ...